PROTEONOMIX, INC. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the Proteonomix, Inc. investment opportunity to institutional investors.

Scheduled for October, Mr. Cohen will discuss with sophisticated investors the recent contract to establish a joint venture with a group of investors that will establish a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.). In addition, Mr. Cohen will discuss the opportunity to set up additional joint ventures in other countries using the U.A.E. arrangement as a model.

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. (”PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies.

**************************************************************

Central Vermont Public Service (NYSE: CV) will purchase two-thirds of the output of Iberdrola Renewables’ planned Deerfield Wind Project in Readsboro and Searsburg, Vt., under an agreement announced recently.

CVPS will purchase 20 megawatts of the project’s planned 30-megawatt output for nine years. Deerfield Wind is proposed to be built on U.S. Forest Service land, near the existing Searsburg wind project, in Readsboro and Searsburg. To protect sensitive contract negotiations with other parties, the price has been disclosed to regulators under seal.

The project is designed to include 15 wind turbines, eight in Searsburg and seven in Readsboro, which will produce 30 megawatts of new capacity. The project is expected to produce enough energy to power about 14,000 average Vermont households.

CV is Vermont’s largest electric utility, serving approximately 159,000 customers statewide. CV’s non-regulated subsidiary, Catamount Resources Corporation, sells and rents electric water heaters through a subsidiary, SmartEnergy Water Heating Services.

**************************************************************

Central Virginia Bankshares, Inc. (NASDAQ: CVBK) and Central Virginia Bank have decided not to pursue a Rights and Stock Offering at this time, on the advice of their investment bankers. The bank expects to renew its efforts to raise additional capital when market conditions improve.

Central Virginia Bankshares, Inc . is the parent of Central Virginia Bank, a 36 year old $470 million community bank with its headquarters and main office in Powhatan County, and six additional branch offices; two branches in the adjacent County of Cumberland, three branches in western Chesterfield County, and one branch in western Henrico County.

**************************************************************

Centrue Financial Corporation (NASDAQ: TRUE), parent company of Centrue Bank , reported a second quarter net loss of $3.9 million. This compares with a net loss of $6.3 million in the first quarter of 2010 and a net loss of $16.2 million in the second quarter of 2009, which included a goodwill impairment charge of $8.5 million. The net loss per common diluted share in the second quarter 2010 was $0.73, compared to net loss of $1.11 in the first quarter of 2010 and net loss of $2.77 in the second quarter 2009. For the first half of 2010, the Company reported a net loss of $10.2 million, or $1.84 per common diluted share, compared to a net loss of $15.2 million, or $2.66 per common diluted share, for the same period in 2009.

Credit costs continued to weigh heavily on second quarter 2010 earnings, as we recorded $7.6 million in provision for loan losses largely related to asset quality deterioration in the Company’s land development, construction and commercial real estate portfolio. Also contributing to the loss was a $1.9 million non-cash credit impairment charge to CDO securities and increased loan remediation costs, including collection expenses on nonperforming loans and expenses associated with maintaining foreclosed real estate. Positively contributing to earnings were gains on sale of the Effingham branch and securities.

Centrue Financial Corporation is a regional financial services company headquartered in St. Louis, Missouri and devotes special attention to personal service. The Company serves a market area which extends from the far western and southern suburbs of the Chicago metropolitan area across Central Illinois down to the metropolitan St. Louis area.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading share from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)

PROTEONOMIX, INC. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon human cells and their derivatives, announced further developments with its Joint Venture Company, XGEN Medical LLC (”XGen”) towards implementing operations in the United Arab Emirates (U.A.E.).

Proteonomix is the majority shareholder in XGen with the balance held by an anonymous investor group. Proteonomix personnel were on the ground in the U.A.E. over the past weeks to work together with the Investor Group through the start up phase. To date, XGen has established an office in the Monarch Office Tower on the prestigious Sheikh Zayed Road, and a residence for visiting Proteonomix personnel on Jumeira 2.

During initial meetings, it was mutually decided to open a local subsidiary corporation in the Dubai free zone. This wholly owned subsidiary will be the vehicle to conduct business in the GCC countries. XGen has filed the corporate papers and has established banking relations with a local bank both for receipt of the initial investment of $5 million and towards further financing expanded services in the region. The Ramadan holiday has slowed progress slightly on these corporate formalities, but full operation of the subsidiary and bank accounts are expected to complete within 30 days.

It was further announced that XGen has expanded its talks within the region beyond a license for manufacture of and treatment with Proteonomix cellular material. Discussions are now further encompassing both the construction of XGen’s own manufacturing and treatment facility within the U.A.E. and on funding phased trials for one or more of Proteonomix’s proprietary cellular materials for treatment of disease.

**************************************************************

Celgene Corporation (NASDAQ:CELG) reports the successful pricing of three series of senior unsecured notes for an aggregate principal amount of $1.25 billion. Of these notes, $500 million will mature in October 2015 and will bear interest at an annual rate of 2.45%, $500 million will mature in October 2020 and will bear interest at an annual rate of 3.95%, and $250 million will mature in October 2040 and will bear interest at an annual rate of 5.70%. The 2.45% notes due October 2015, the 3.95% notes due October 2020, and the 5.70% notes due October 2040 were priced to yield 2.481%, 3.981%, and 5.713%, respectively.

Celgene expects to use the net proceeds from the offering for general corporate purposes, which may include, without limitation, further development of Celgene’s clinical and preclinical programs, expansion of Celgene’s international operations, capital expenditures, strategic transactions and to meet working capital needs. The offering is expected to close on October 7, 2010.

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.

**************************************************************

Cell Therapeutics, Inc. (NASDAQ:CTIC) reports the results from its Annual Meeting of Shareholders held on Thursday, September 16, 2010.

At the Annual Meeting, shareholders elected John H. Bauer and Phillip M. Nudelman, M.D. to serve on the Company’s Board of Directors until the Company’s 2013 Annual Meeting. Shareholders approved the proposals to amend the Company’s amended and restated articles of incorporation to increase the total number of authorized shares and authorized shares of common stock and amend the Company’s 2007 Equity Incentive Plan, as amended (the “Plan”), to increase the number of shares available for issuance under the Plan. Shareholders ratified the selection of Stonefield Josephson, Inc. as the Company’s independent auditors for the year ending December 31, 2010.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable.

**************************************************************

Cellcom Israel Ltd. (NYSE: CEL) reported recently that the Ministry of Communications, or MOC, published a UMTS spectrum tender for two additional UMTS operators. Participation will be allowed for new operators and Mirs Communications Ltd., or Mirs (an existing niche operator). The winners will be awarded a general license for the provision of cellular services (in Mirs’ case, its current license shall be amended). The tender does not set a completion date for the tender process. The tender conditions are subject to changes.

Cellcom Israel Ltd., established in 1994, is the leading Israeli cellular provider; Cellcom Israel provides its approximately 3.341 million subscribers (as at June 30, 2010) with a broad range of value added services including cellular and landline telephony, roaming services for tourists in Israel and for its subscribers abroad and additional services in the areas of music, video, mobile office etc., based on Cellcom Israel’s technologically advanced infrastructure. The Company operates an HSPA 3.5 Generation network enabling advanced high speed broadband multimedia services, in addition to GSM/GPRS/EDGE and TDMA networks. Cellcom Israel offers Israel’s broadest and largest customer service infrastructure including telephone customer service centers, retail stores, and service and sale centers, distributed nationwide. Through its broad customer service network Cellcom Israel offers its customers technical support, account information, direct to the door parcel services, internet and fax services, dedicated centers for the hearing impaired, etc. As of 2006, Cellcom Israel, through its wholly owned subsidiary Cellcom Fixed Line Communications L.P., provides landline telephone communication services in Israel, in addition to data communication services.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading share from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)

PROTEONOMIX, INC. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, reports that Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the Proteonomix, Inc . investment opportunity to institutional investors.

Scheduled for early October, Mr. Cohen will discuss with sophisticated investors the recent contract to establish a joint venture with a group of investors that will establish a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.). In addition, Mr. Cohen will discuss the opportunity to set up additional joint ventures in other countries using the U.A.E. arrangement as a model.

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. (”PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies.

**************************************************************

CARBO Ceramics Inc. (NYSE: CRR) plans to release earnings results for the third quarter of 2010 on October 28, 2010, and will host a conference call at 10:00 a.m. Central Time (11:00 a.m. Eastern) that day. The call will be hosted by Gary Kolstad, President and CEO, and Ernesto Bautista, III, Vice President and CFO.

CARBO is the world’s largest supplier of ceramic proppant for fracturing oil and gas wells; the provider of the world’s most popular fracture simulation software; and a provider of fracture design and consulting services. The Company also provides a broad range of technologies for spill prevention, containment and countermeasures, along with geotechnical monitoring.

**************************************************************

Cardinal Health (NYSE:CAH) plans to release first-quarter financial results for its fiscal 2011 on Oct. 28, prior to the opening of trading on the New York Stock Exchange.

The company has scheduled a webcast and conference call for Oct. 28 at 8:30 a.m. EDT to discuss first-quarter results. To access the call and corresponding slide presentation, go to the Investor page at cardinalhealth.com/investors or dial 617-213-4848 passcode 23771725.

Headquartered in Dublin, Ohio, Cardinal Health, Inc. is a $99 billion health care services company that improves the cost-effectiveness of health care. As the business behind health care, Cardinal Health helps pharmacies, hospitals, ambulatory surgery centers and physician offices focus on patient care while reducing costs, improving efficiency and quality, and increasing profitability. Cardinal Health is an essential link in the health care supply chain, providing pharmaceuticals and medical products to more than 60,000 locations each day. The company is also a leading manufacturer of medical and surgical products, including gloves, surgical apparel and fluid management products. In addition, the company supports the growing diagnostic industry by supplying medical products to clinical laboratories and operating the nation’s largest network of radiopharmacies that dispense products to aid in the early diagnosis and treatment of disease. Ranked #17 on the Fortune 500, Cardinal Health employs more than 30,000 people worldwide.

**************************************************************

CareFusion (NYSE: CFN), a leading, global medical device company, has announced it has entered into an agreement with Healthpoint, Ltd. to market and sell innovative surgical scrub solutions, including Surgicept Waterless Surgical Hand Scrub, Triseptin Water-Aided Surgical Scrub and Triseptin Hand and Body Antiseptic.

It has been established that HAIs can be reduced with proper hand antisepsis by health care professionals prior to surgery, which limits the transfer of potentially harmful microorganisms to the skin of their patients. Recommendations and guidelines, including those from the U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO), state that health care professionals should clean their hands with an alcohol-based antimicrobial solution prior to patient contact or putting on gloves. However, adherence to these guidelines is lower than it should be; studies have shown an average compliance rate of 40 percent. According to the CDC, poor compliance is due to multiple factors, including perceived lack of time and irritation or dryness caused by the antiseptic.

CareFusion is a global corporation serving the health care industry with products and services that help hospitals measurably improve patient care. The company develops market-leading technologies including Alaris IV pumps, Pyxis automated dispensing and patient identification systems, AirLife, AVEA and LTV series of ventilators and respiratory products, ChloraPrep skin prep products, MedMined services for infection surveillance, V. Mueller and Snowden-Pencer surgical instruments and NeuroCare diagnostic products. CareFusion employs more than 15,000 people across its global operations.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading share from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)

PROTEONOMIX, INC. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon human cells and their derivatives, announced further developments with its Joint Venture Company, XGEN Medical LLC (”XGen”) towards implementing operations in the United Arab Emirates (U.A.E.).

Proteonomix is the majority shareholder in XGen with the balance held by an anonymous investor group. Proteonomix personnel were on the ground in the U.A.E. over the past weeks to work together with the Investor Group through the start up phase. To date, XGen has established an office in the Monarch Office Tower on the prestigious Sheikh Zayed Road, and a residence for visiting Proteonomix personnel on Jumeira 2.

During initial meetings, it was mutually decided to open a local subsidiary corporation in the Dubai free zone. This wholly owned subsidiary will be the vehicle to conduct business in the GCC countries. XGen has filed the corporate papers and has established banking relations with a local bank both for receipt of the initial investment of $5 million and towards further financing expanded services in the region.

It was further announced that XGen has expanded its talks within the region beyond a license for manufacture of and treatment with Proteonomix cellular material. Discussions are now further encompassing both the construction of XGen’s own manufacturing and treatment facility within the U.A.E. and on funding phased trials for one or more of Proteonomix’s proprietary cellular materials for treatment of disease.

**************************************************************

Calix, Inc. (NYSE: CALX) reports that Broadband Stimulus award winners Wikstrom Telephone Company, Inc. (Wiktel) and Reedsburg Utility Commission (Reedsburg) have selected the Calix Unified Access portfolio to address their respective “Fiber Forward” initiatives. The awards, which include plant engineering, materials, labor, and other costs, including access equipment, will together result in over $14.9 million dollars of grants, loans, and private investment. Both awards will be used to deploy additional services in “unserved” and “underserved” rural areas of northwestern Minnesota and central Wisconsin, bringing much needed broadband access services and the opportunity for future economic development to each respective region.

Calix is a leading provider in North America of broadband communications access systems and software for copper- and fiber- based network architectures that enable communications service providers to connect to their residential and business subscribers. Calix has shipped seven million ports of its Unified Access Infrastructure portfolio to more than 500 North American and international customers, whose networks serve over 40 million subscriber lines in total.

**************************************************************

Callaway Golf Company (NYSE: ELY) and Automobili Lamborghini S.p.A. have signed an agreement to connect the resources of their world-renowned Research and Development teams. This unique alliance establishes an ongoing collaboration to develop innovative technologies and materials designed to enhance the performance of each company’s products. The partnership, as well as the introduction of a new, co-developed material called Forged Composite(TM), was officially celebrated recently at the 2010 Paris Motor Show by Automobili Lamborghini President and CEO Stephan Winkelmann and George Fellows, President and CEO, Callaway Golf.

The origins of this now formalized relationship date back several years. Through the constant pursuit of lighter and stronger materials that improve the performance of their products, the Lamborghini and Callaway Research and Development teams cultivated similar areas of expertise. A major point of convergence surrounded the development of advanced composite structures. These highly developed materials comprised of microscopic carbon fibers feature superior strength and performance characteristics in comparison to the metal alloys that are generally used throughout the automotive and golf industries.

Through an unwavering commitment to innovation, Callaway Golf Company creates products and services designed to make every golfer a better golfer. Callaway Golf Company manufactures and sells golf clubs and golf balls, and sells golf apparel, footwear and accessories, under the Callaway Golf, Odyssey, Top-Flite, and Ben Hogan brands in more than 110 countries worldwide.

**************************************************************

Callon Petroleum Company (NYSE: CPE) provided an update on its onshore drilling activity, increase in reserves and management changes.

OPERATIONAL HIGHLIGHTS

* Proved reserves increased to 13.0 million net barrels of oil equivalent (MMBoe) at September 1, 2010, representing a 34% increase from December 31, 2009. Reserve additions were primarily driven by Callon’s successful development drilling activity in the Permian Basin and Haynesville Shale plays.
* Production from the Wolfberry oil play in the Permian Basin is currently 500 net barrels of oil equivalent per day (Boe/d) up 43% since year end 2009. The company has added a second rig in the play and forecasts production to approach a 1,000 net Boe/d exit rate by year-end.
* First production from the George R. Mills Well No. 1H in the Haynesville Shale commenced on September 3, 2010. The well is currently producing at a restricted rate of 10-12 million gross cubic feet of natural gas equivalent per day (MMcfe/d).
* Gary Newberry has been promoted to Senior Vice President – Operations, as Steve Hinchman leaves to become Chief Executive Officer of another E&P company.

Callon Petroleum Company is engaged in the acquisition, development, exploration and operation of oil and gas properties in Louisiana, Texas, and the offshore waters of the Gulf of Mexico.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading share from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)

_____

Last Price: $22.95 , UP $2.30 (11.11%)

Gold Resource Corporation Executes $55.6 Million Private Placement to Accelerate Production Profile and Exploration

Gold Resource Corporation (GORO) (AMEX: GORO) is pleased to announce the execution of agreements for a $55.6 million private placement of its common stock to increase the development of its Oaxaca Mining Unit’s production profile, accelerate its exploration programs, initiate a formal reserve report and to capitalize on new property acquisition opportunities. Gold Resource Corporation is a low-cost gold producer with operations in southern Mexico.

Gold Resource Corporation’s private placement consists of 3.475 million shares of restricted common stock at $16.00 per share with no warrants. Jefferies & Company, Inc. served as sole placement agent for Gold Resource Corporation in the private placement. Closing of the transaction is subject to customary conditions.

The Company intends to increase mill capacity by potentially 50% in anticipation of expansion of its known mineralization at the La Arista vein system and thereby correspondingly increase the Project’s production profile. The Company will accelerate exploration of the Oaxaca Mining Unit’s portfolio of 5 potential high-grade properties. Having drilled only 1% of the Oaxaca Mining Unit’s concessions to date, and finding three high-grade deposits, an aggressive investment in exploration is warranted and could have a positive, near-term impact on shareholder value. A more formal reserve report of the internally estimated mineralized material will be undertaken. And, the Company will also be in the position to acquire additional property opportunities located in select areas throughout Mexico and worldwide for project diversification and Company growth.

Gold Resource Corporation is positioned for accelerated and aggressive growth during this historic gold bull market. The equity raise provides immediate funding to accelerate the Company’s production profile and to accelerate exploration of its Oaxaca Mining Unit. Management believes the potential 50% mill capacity increase coupled with the ability to accelerate exploration programs on a more comprehensive and immediate basis more than offsets the 7% shareholder dilution. With only 53 million shares outstanding after the raise, the Company is among the tightest capital structures for a producing company in the mining space.

Gold Resource Corporation, an exploration stage company, engages in the exploration for and production of gold, silver, precious metals, and base metals, including copper, lead, and zinc primarily in Mexico. It holds a 100% interest in five properties, including the El Aguila property, the Las Margaritas property, the El Rey property, the Solaga property, and the Alta Gracia property in southern state of Oaxaca. The company was founded in 1998 and is based in Denver, Colorado.

http://www.goldresourcecorp.com

_____

Last Trade: $64.45 , UP $1.79 (2.86%)

Park National Corporation Reports Second Quarter 2010 Financial Results and Declares Quarterly Cash Dividend

Park National Corporation (Park) (NYSE Amex:PRK) recently announced operating results for the three and six months ended June 30, 2010 (second quarter and first half of 2010). Park’s Board of Directors also today declared a $0.94 per common share quarterly cash dividend, payable on September 10, 2010 to common shareholders of record as of August 25, 2010.

“We are pleased to report business loan growth in the second quarter of this year. Also, extraordinarily low residential mortgage rates continue to help generate significant consumer lending activity, including $244 million in mortgage loan originations for the first half of 2010,” said Park Chairman C. Daniel DeLawder. “Our lenders are focused on supporting each community we serve through high-quality, reliable lending with consistent underwriting. As economic conditions slowly improve, we hope to further expand our loan balances and reduce problem credits.”

Park’s second quarter net income was $21.2 million, compared to $21.3 million for the same period in 2009. Net income was $41.9 million for first half of 2010, a 1.8 percent decline from the first half of 2009 net income of $42.7 million.

Net income for Park’s Ohio-based operations was $56.2 million for the first half of 2010, a 5.4 percent increase from the $53.3 million reported in the first half of 2009. Net income for Park’s Ohio-based operations was $27.9 million for the second quarter of 2010, the same as the $27.9 million reported in the second quarter of 2009.

Headquartered in Newark, Ohio, Park National Corporation has $7.1 billion in total assets (as of June 30, 2010). Park consists of 13 community bank divisions and two specialty finance companies. Park’s Ohio-based banking operations are conducted through Park subsidiary The Park National Bank and its divisions which include Fairfield National Bank Division, Richland Bank Division, Century National Bank Division, First-Knox National Bank Division, Farmers & Savings Bank Division, United Bank Division, Second National Bank Division, Security National Bank Division, Unity National Bank Division and The Park National Bank of Southwest Ohio & Northern Kentucky Division.

http://www.parknationalcorp.com

_____

Proteonomix, Inc. (OTCBB: PROT.OB)

Last Trade: $1.85 , UP $0.23 (14.20%)

The Science Behind our Cutting-Edge Skin Care Products

How It Works

Proteoderm has used its expertise in protein technology to develop a unique, natural matrix of proteins called Matrix NC-138T for use in anti-aging skin products.

Matrix NC-138

Bioactive proteins have been defined as specific proteins that have a positive impact on body functions or conditions and may ultimately influence health.

The activity of these biofunctional proteins contained in the isolated Matrix NC-138T NC-138 is based on their inherent amino acid composition and sequence. MatrixNC-138T acts on the skin to enhance activities through the stimulation of collagen and glandular production leading to a reduction of wrinkles.

Anti-Aging Technology

This company may be able to reverse the signs of aging without Botox injections.

Proteoderm is another subsidiary of Proteonomix.

Proteoderm’s expertise in biotechnology led to the development of cutting edge anti-aging skin care products. The Proteoderm system works to revitalize and rejuvenate your own cells to help drastically reverse the effects of aging!

Among the many cosmetic actives available, proteins have garnered substantial interest for several years. The main reason is that one of the properties of proteins is the delivery of a chemical message that up or down regulates particular cell functions. An accepted view of protein activity is that their amino-acid constituents have structures which send specific signals to the specific cells, for example to the fibroblasts to increase collagen production.

Particular proteins are therefore ideal cosmetic ingredients that can be used to counteract the formation of wrinkles and loss of skin elasticity. Proteoderm has used its expertise in proteomics and protein technology to develop a unique natural matrix of proteins called MatrixTM NC-138 for use in anti-aging skin products.

About Proteonomix, Inc.

Proteonomix, Inc., a biotechnology company, engages in the development of stem cell therapies primarily for the treatment of diabetes and cardiac therapy, as well as offers cosmeceutical products.

The stem cell therapy involves the introduction of healthy new stem cells to repair and replace damaged or lost cells. It offers product for the treatment of anti-aging and damaged skin. The company develops cosmetic products using its technologies, Secreted Matrix and Matrix NC-138 that is a stem cell derived proteins technology.

It also involves in the operation of retail Web site, Proteoderm.com to sell its anti-aging line of skin care products; develops therapeutic modalities for the treatment of cardiovascular disease; and engages in the reproductive tissue banking, including sperm, ova, ovarian tissue, and testicular tissue.

In addition, the company develops intellectual properties for patent applications, including a medium and scaffolding for enhancing the growth of stem cells, a growth platform for stem cells, a cord blood banking cryopreservation bag, and a device to eliminate malformed stem cells via filtration.

Further, it is developing pre-clinical-stage therapeutic agents and treatments for cancer, diabetes, heart, lung, and kidney diseases, as well as for stem cell bone marrow and organ transplants. The company was formerly known as National Stem Cell Holding, Inc. and changed its name to Proteonomix, Inc. in August 2008. Proteonomix was founded in 2005 and is based in Mountainside, New Jersey.

http://www.proteonomix.com/

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading share from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)